Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial
N Engl J Med. 2007 356 (22): 2271-81

PMID: 17538086 · DOI:10.1056/NEJMoa066838

MeSH Terms (20)

Adult Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Female Hematologic Diseases Humans Interferon-alpha Kidney Neoplasms Male Middle Aged Prognosis Proportional Hazards Models Protein Kinase Inhibitors Protein Kinases Sirolimus Survival Analysis TOR Serine-Threonine Kinases

Connections (1)

This publication is referenced by other Labnodes entities:

Links